Reproductive history and exogenous hormonal exposures are acknowledged risk factors for breast cancer in the general population. In women at increased breast cancer risk for genetic predisposition or positive family history, data regarding these risk factors are limited or conflicting, and recommendations for these categories are unclear. We evaluated the characteristics of reproductive life in 2522 women at increased genetic or familial breast cancer risk attending our Family Cancer Center. Breast cancers in BRCA mutation carriers were more likely to be hormone receptor negative, diagnosed at 35 years or before and multiple during the lifetime than tumors in women at increased familial risk, while the distribution of invasive cancers and HER2 positive tumors was similar in the different risk groups. At least one full-term pregnancy (HR 0.27; 95% CI 0.12-0.58; p = 0.001), breastfeeding either less (HR 0.24; 95% CI 0.09-0.66; p = 0.005) or more (HR 0.25; 95% IC 0.08-0.82; p = 0.022) than one year and late age at menopause (HR 0.10; 95% CI 0.01-0.82; p = 0.033) showed to be protective factors in BRCA mutation carriers, while in women at increased familial risk early age at first full-term pregnancy (HR 0.62; 95% IC 0.38-0.99; p = 0.048) and late menarche (HR 0.61; 95% CI 0.42-0.85; p = 0.004) showed to be the main protective factors. Finally, for the entire population, combined hormonal contraceptives demonstrated to do not increase breast cancer risk. The results of our study suggest that women at high familial risk and mutation carries develop tumors with different clinical-pathological characteristics and, consequently, are influenced by different protective and risk factors.

The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation / Toss, A.; Grandi, G.; Cagnacci, A.; Marcheselli, L.; Pavesi, S.; De Matteis, E.; Razzaboni, E.; Tomasello, C.; Cascinu, S.; Cortesi, L.. - In: ONCOTARGET. - ISSN 1949-2553. - 8:6(2017), pp. 9144-9154. [10.18632/oncotarget.13423]

The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation

Toss A.
;
Grandi G.;Cagnacci A.;Marcheselli L.;Razzaboni E.;Tomasello C.;Cascinu S.;
2017

Abstract

Reproductive history and exogenous hormonal exposures are acknowledged risk factors for breast cancer in the general population. In women at increased breast cancer risk for genetic predisposition or positive family history, data regarding these risk factors are limited or conflicting, and recommendations for these categories are unclear. We evaluated the characteristics of reproductive life in 2522 women at increased genetic or familial breast cancer risk attending our Family Cancer Center. Breast cancers in BRCA mutation carriers were more likely to be hormone receptor negative, diagnosed at 35 years or before and multiple during the lifetime than tumors in women at increased familial risk, while the distribution of invasive cancers and HER2 positive tumors was similar in the different risk groups. At least one full-term pregnancy (HR 0.27; 95% CI 0.12-0.58; p = 0.001), breastfeeding either less (HR 0.24; 95% CI 0.09-0.66; p = 0.005) or more (HR 0.25; 95% IC 0.08-0.82; p = 0.022) than one year and late age at menopause (HR 0.10; 95% CI 0.01-0.82; p = 0.033) showed to be protective factors in BRCA mutation carriers, while in women at increased familial risk early age at first full-term pregnancy (HR 0.62; 95% IC 0.38-0.99; p = 0.048) and late menarche (HR 0.61; 95% CI 0.42-0.85; p = 0.004) showed to be the main protective factors. Finally, for the entire population, combined hormonal contraceptives demonstrated to do not increase breast cancer risk. The results of our study suggest that women at high familial risk and mutation carries develop tumors with different clinical-pathological characteristics and, consequently, are influenced by different protective and risk factors.
2017
8
6
9144
9154
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation / Toss, A.; Grandi, G.; Cagnacci, A.; Marcheselli, L.; Pavesi, S.; De Matteis, E.; Razzaboni, E.; Tomasello, C.; Cascinu, S.; Cortesi, L.. - In: ONCOTARGET. - ISSN 1949-2553. - 8:6(2017), pp. 9144-9154. [10.18632/oncotarget.13423]
Toss, A.; Grandi, G.; Cagnacci, A.; Marcheselli, L.; Pavesi, S.; De Matteis, E.; Razzaboni, E.; Tomasello, C.; Cascinu, S.; Cortesi, L.
File in questo prodotto:
File Dimensione Formato  
13423-200385-3-PB.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 706.96 kB
Formato Adobe PDF
706.96 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1179846
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 26
social impact